Mao Yinqi, Chen Wei, Wu Han, Liu Chenbin, Zhang Jingjun, Chen Shuying
School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Department of Rehabilitation, Huashan Hospital Affiliated to Fudan University, Shanghai, People's Republic of China.
Onco Targets Ther. 2021 Jan 5;13:13479-13490. doi: 10.2147/OTT.S288791. eCollection 2020.
Hepatocellular carcinoma (HCC) is one of the most common clinically malignant tumors of the digestive system. It ranks the sixth most common malignant tumor in the world and ranks fourth among cancer-related death worldwide. At present, early diagnosis and prognosis monitoring of hepatocellular carcinoma mainly use alpha-fetoprotein combined with ultrasonography, which leads to clinical frequently missed diagnosis or even misdiagnosis. Therefore, seeking specific diagnostic and monitoring molecules of hepatocellular carcinoma are still hot topics in contemporary medical practice. MicroRNA is an endogenous non-coding small RNA that regulates the expression of the target molecule and participates in various biological processes in vivo. The miR-200 family, the most common celebrity family of microRNAs, is commonly lower expression in a variety of cancers and is closely associated with tumorigenesis and outcome, especially hepatocellular carcinoma. This review mainly discusses the expression changes, specific molecular mechanisms, biological functions and clinical values of miR-200 family in hepatocellular carcinoma. Moreover, we highlighted utilization of miR-200 family as molecular biomarkers for early diagnosis, prognostic monitoring and appropriate therapy in hepatocellular carcinoma.
肝细胞癌（HCC）是消化系统临床上最常见的恶性肿瘤之一。它是世界上第六大常见恶性肿瘤，在全球癌症相关死亡中排名第四。目前，肝细胞癌的早期诊断和预后监测主要采用甲胎蛋白联合超声检查，这导致临床上经常漏诊甚至误诊。因此，寻找肝细胞癌的特异性诊断和监测分子仍然是当代医学实践中的热点话题。微小RNA是一种内源性非编码小RNA，可调节靶分子的表达并参与体内各种生物学过程。miR-200家族是最常见的微小RNA明星家族，在多种癌症中通常表达较低，并且与肿瘤发生和预后密切相关，尤其是肝细胞癌。本综述主要讨论miR-200家族在肝细胞癌中的表达变化、特定分子机制、生物学功能和临床价值。此外，我们强调了miR-200家族作为肝细胞癌早期诊断、预后监测和适当治疗的分子生物标志物的应用。
